The abstract is read at the publisher; the summary is JClub's.
In 368 adults with MASLD in the Duke biorepository, statin use is linked to lower ALT, AST, and LDL—especially in older individuals—and to transcriptomic suppression of senescence pathways.
- Why it matters: Older age increases susceptibility to MASLD, yet it is unclear whether statins change liver aging regulators and how responses differ by age and sex.
- What they did: The study analyzed matched liver transcriptomes and clinical data from 368 adults, then tested whether senescence and ferroptosis-related pathways differed by statin use, including after propensity score matching and in an independent obese cohort.
- The result: Statin use is associated with suppression of senescence-related pathways and increased activation of ferroptosis-linked pathways, implying age-dependent liver remodeling and potential senolytic-like effects in this MASLD context.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.